High-dose vitamin D supplementation in multiple sclerosis – results from the randomized EVIDIMS (efficacy of vitamin D supplementation in multiple sclerosis) trial
J Multiple Sclerosis Journal – Experimental, Translational and Clinical, https://doi.org/10.1177/2055217320903474
an Dörr*†, Priscilla Bäcker-Koduah*, Klaus-Dieter Wernecke, ...
This EVIDIMS Randomized Controlled trial used 20,400 IU of Vitamin D every second day
Some success was achieved (see table below)
Dr. Coimbra's protocol customizes the treatment for each MS patient
Thus it cannot be run as a Randomized Controlled Trial
Vitamin D is not a single magic bullet - many other nutrients are used
One (dose) size does not fit all - The Coimbra Protocol uses 2X to 15X as much vitamin D
- Overview MS and vitamin D
- Multiple Sclerosis treated when use high doses of vitamin D – meta-analysis May 2018
- Multiple Sclerosis: number needed to treat with vitamin D may be as low as 1.3 – Meta-analysis Oct 2013
- Multiple Sclerosis risk increased due to genes - 22nd study – Aug 2017
- Multiple Sclerosis relapses cut in half by bi-weekly 100,000 IU of Vitamin D – RCT 2019
UV and Sunshine reduces MS risk
- Multiple Sclerosis 2X more likely if low winter UV – June 2018
- Multiple Sclerosis half as likely if get plenty of sunshine (not a news item) – March 2018
Other things also help
- Multiple Sclerosis treated by 50,000 IU Vitamin D bi-weekly plus Omega-3 – RCT July 2018
- Multiple Sclerosis 40 percent less likely if consume tinned fish (Vitamin D and Omega-3) – Sept 2019
- Resveratrol treats Multiple Sclerosis and other autoimmune diseases – many studies
- Not a single case of multiple sclerosis in 15,000,000 people (plant-based diets)
High Dose Vitamin D and cofactors
- The use of high dose Vitamin D (Coimbra Protocol) for multiple sclerosis in Germany – 2019
- Successful high dose vitamin D (Coimbra Protocol) should be evaluated – June 2019
- Comparing High-dose vitamin D therapies MS and other health problems
Number of MS studies which are also in other categories
20 studies in Genetics - genes can restrict Vitamin D getting to the blood and to the cells 10 studies in Vitamin D Receptor - gene which restricts D from getting to the cells 5 studies in Vitamin D Binding Protein - gene which restricts D from getting to the cells 19 studies in Ultraviolet light - may be even better than Vitamin D in preventing and treating MS 9 studies in Omega-3 - which helps Vitamin D prevent and treat MS
Epidemiological, preclinical, and non-interventional studies link vitamin D (VD) serum levels and disease activity in multiple sclerosis (MS). It is unclear whether high-dose VD supplementation can be used as an intervention to reduce disease activity.
The study aimed to compare the effects of every other day high- (20,400 IU) versus low-dose (400 IU) cholecalciferol supplementation on clinical and imaging markers of disease activity in patients with relapsing–remitting MS or clinically isolated syndrome.
The EVIDIMS (efficacy of vitamin D supplementation in multiple sclerosis) trial was a multicentre randomized/stratified actively controlled explorative phase 2a pilot trial with a double-blind intervention period of 18 months, add on to interferon-β1b.
Fifty-three patients were randomized, and 41 patients completed the study. Cholecalciferol supplementation was well tolerated and safe in both arms. After 18 months, clinical (relapse rates, disability progression) and radiographical (T2-weighted lesion development, contrast-enhancing lesion development, brain atrophy) did not differ between both treatment arms. Post-study power calculations suggested that the sample size was too low to prove the hypothesis.
The results neither support nor disprove a therapeutic benefit of high-dose VD supplementation but provide a basis for sound sample size estimations in future confirmatory studies. www.clinicaltrials.gov/NCT01440062
151 visitors, last modified 25 Jan, 2020, URL: